Table 2.
Univariate and multivariate analysis of variables for association with ≥ 30% improvement in liver stiffness measurement.
| Variable | Univariate | P-value | Multivariate | P-value |
|---|---|---|---|---|
| Odds ratio (95% CI) | Odds ratio (95% CI) | |||
| Age (yrs) | 0.99 (0.96–1.03) | .765 | ||
| Female gender | 0.87 (0.40–1.91) | .726 | ||
| BMI (kg/m2) | 1.03 (0.95–1.12) | .526 | ||
| Diabetes mellitus | 1.32 (0.39–4.43) | .658 | ||
| Genotype 3 | 0.50 (0.23–1.08) | .078 | ||
| Baseline elevated AST | 1.00 (0.99–1.01) | .548 | ||
| Baseline elevated ALT | 1.00 (0.99–1.01) | .914 | ||
| Baseline elevated ALP | 0.98 (0.97–0.99) | .026* | 0.98 (0.97–0.99) | .010* |
| Baseline TE ≥ 9.5 kPa | 2.41 (1.01–5.73) | .047* | 3.04 (1.22–7.60) | .017* |
| Baseline TE ≥ 13.5 kPa | 2.00 (0.92–4.34) | .079 | ||
| Peg-IFN-free treatment regimens | 1.85 (0.86–3.99) | .117 |
ALP = Alkaline phosphatase, ALT = Alanine aminotransferase, AST = Aspartate aminotransferase, BMI = body mass index, Peg-IFN = Pegylated interferon, TE = Transient elastography.